Uniogen’s product portfolio includes unique glycovariant immunoassays for the early and timely diagnostics of cancer. Our assay technology is based on nanoparticles coated with glycan binders at a high density, which translates to an improved sensitivity and specificity compared to conventional biomarker assays. The functional binding affinity of a coated nanoparticle is superior to individual binders due to the high number of binder molecules on an individual particle.
Uniogen’s first proprietary test for the early detection of ovarian cancer is currently under development. Although ovarian cancer is a common malignancy with a relatively high mortality, no clinical screening method or early-stage diagnostic tool has been available up to date. In addition, we have patents for testing of other cancer types, such as pancreatic, breast and intestinal cancers.